BioCentury | Aug 15, 2019
Distillery Techniques

Mutation combination as endometrial cancer biomarker

...Grand Rapids, Mich.; Spectrum Health System, Grand Rapids, Mich. e-mail: rlc@msu.edu Sandi Wong Michigan State University Van Andel Institute AT-rich interaction domain 1A (ARID1A) Phosphoinositide...
BioCentury | Aug 9, 2019
Preclinical News

Aug. 8 Preclinical Quick Takes: Mayo Clinic assay for residual disease; plus camouflage for bacterial agents, Elicio's KRAS vaccine and more

...BioMed Mayo Clinic Michigan State University NovaDigm Therapeutics Inc. Shanghai Jiao Tong University Tara Biosystems Inc. Van Andel Institute Agglutinin-like sequence 3 (ALS3) AT-rich interaction domain 1A (ARID1A) CC...
BioCentury | May 23, 2018
Translation in Brief

Toward Tailored Chemo

A group at UCSF is bringing precision medicine to chemotherapies, with a predictive model for drug responses based on single gene deletions. Despite advances in immuno-oncology and targeted therapies, nearly 95% of cancer patients receive...
BioCentury | May 15, 2018
Distillery Techniques

Biomarkers; other

TECHNOLOGY: Gene profiling; computational models A gene profiling-based computational model could identify single-gene deletions as markers of response to therapies for high-grade serous ovarian cancer (HGSOC) patients. The model is generated by transfecting a human...
BioCentury | Apr 20, 2018
Company News

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
BioCentury | Apr 16, 2018
Tools & Techniques

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Nov 6, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of SMARCA2 RNA could help predict responses to EZH2 inhibitors in cancers harboring mutations in the SWI/SNF complex. In 20 human ovarian, lung, gastrointestinal and other cancer cell lines with...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting HDAC6 could help treat ARID1A -mutant clear cell ovarian cancer. In four ARID1A-mutant clear cell ovarian cancer cell lines, the HDAC6 inhibitor rocilinostat or shRNA...
BioCentury | Jun 2, 2017
Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, CASI Pharmaceuticals Inc. (NASDAQ:CASI) reported data from 37 evaluable patients with recurrent clear cell ovarian cancer in a Phase II...
Items per page:
1 - 10 of 17